

SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOLUME 15 INDEX

AUTHOR INDEX

- | | | | |
|---------------------------|-----------------------------------|-------------------------------------|--------------------------------|
| Adams SL, 261 | Degryse E, 288 | Hoppensteadt DA, 316, 378, 386, 440 | Panak E, 167 |
| Aillaud MF, 390 | Delebassee D, 159, 288 | | Payne PW, 302 |
| Alessandri C, 226 | De Rubertis C, 464 | | Pescador R, 474 |
| Alessi MC, 390 | De Seze O, 373 | Johnson PH, 302 | Pifarri R, 173, 316 |
| Arbogast H, 250 | Didisheim P, 240 | Juhan-Vague I, 390 | Polizze C, 464 |
| Arcan JC, 167 | Di Marcotullio G, 464 | | Porta R, 474 |
| Augustin J, 414 | Doutremepuich C, 373 | Kim DU, 206 | Prino G, 474 |
| | Doutremepuich F, 373 | Kwaan HC, 353 | |
| | Drouet L, 111 | | Quintarelli C, 226 |
| Baker Jr. WF, 1 | Eldor A, 215 | Lalanne MC, 373 | |
| Bakhos M, 173 | Elias A, 390 | Lazar JB, 302 | Racanelli A, 378, 386, 440 |
| Balsano F, 226 | Engelberg H, 178 | Legrand DR, 200 | Riehl-Bellon N, 288 |
| Bang NU, 88 | | Lemoine Y, 288 | Riess H, 250 |
| Bassand JP, 435 | Faivre R, 435 | Liang MD, 259 | Roitsch C, 288 |
| Bernat A, 159, 288 | Fareed J, 230, 316, 378, 386, 440 | Loison G, 288 | |
| Bianchini P, 365 | Faulk WP, 88 | | Saliola M, 266 |
| Bieghold M, 409 | Fears R, 129 | Maffrand JP, 159, 288 | Seiffge D, 150 |
| Biffani G, 464 | Fenton II. JW, 265 | Malinconico U, 464 | Serradimigni A, 390 |
| Blakeman B, 173 | Ferro D, 226 | Mantovani M, 474 | Shichman D, 259 |
| Blumel G, 424 | Fink E, 283 | Markwardt F, 269 | Soria C, 435 |
| Boccardi L, 464 | Foy BK, 173 | Mattioli G, 470 | Soria J, 435 |
| Born GVR, 140 | Frisch EP, 341 | Matzner Y, 215 | Stassen JM, 390 |
| Bourgain R, 184 | Fuks Z, 215 | Maurat JP, 435 | Stehle G, 414 |
| Braquet P, 184 | Fusaro MT, 470 | McIntyre JA, 88 | Stiegler H, 250 |
| Breddin HK, 144, 237, 401 | | Mencia-Huerta JM, 184 | Sullivan HJ, 173 |
| Brown SW, 288 | | Messmore Jr. HL, 405 | Sze P, 302 |
| | Gallus AS, 99 | Meuleman DG, 370 | |
| Caen JP, 111, 359, 435 | Gardner AL, 200 | Milazotto F, 464 | Talbot M, 293 |
| Capello C, 470 | Gargiulo P, 88 | Minardi G, 464 | Tobelem G, 197 |
| Caprini JA, 244 | Giampaolo P, 464 | Mirshahi M, 435 | Toulemonde F, 373, 395 |
| Carelli M, 464 | Giovannini E, 464 | Montoya A, 173 | Tubaro M, 464 |
| Carroll JJ, 334 | Grau A, 250 | Müller-Berghaus G, 58 | |
| Cazenave JP, 288 | Greisler HP, 206 | | Vinazzer H, 347 |
| Choay J, 359 | Grieco J, 173 | Narayanan K, 259 | Violi F, 226 |
| Citone C, 464 | Gurewicz V, 123 | Natonson RA, 244 | Vlodavsky I, 215 |
| Collen D, 390 | Guyot M, 373 | Nazzari M, 464 | |
| Compton R, 200 | | Nees S, 250 | Walenga JM, 230, 316, 378, 440 |
| Cornelli U, 230, 464 | Haas S, 424 | Neuhart E, 435 | Weithman KU, 150 |
| Courtney M, 288 | Halder A, 250 | Niada R, 474 | Winant R, 302 |
| Coyne E, 440 | Harenberg J, 414 | | Witte LD, 215 |
| | Herring MB, 200 | O'Brien JR, 171 | Zimmermann R, 414 |
| Defreyn G, 159, 288 | | | |

CUMULATIVE TABLE OF CONTENTS

Number 1

DISSEMINATED INTRAVASCULAR COAGULATION: II Rodger L. Bick, M.D., F.A.C.P.

- Clinical Aspects of Disseminated Intravascular Coagulation: A Clinician's Point of View,** William F. Baker, Jr., M.D., F.A.C.P.
Pathophysiologic and Biochemical Events in Disseminated Intravascular Coagulation: Dysregulation of Procoagulant and Anticoagulant Pathways, Gert Müller-Berghaus, M.D.
Hemostasis and Fibrinolysis in Renal Transplantation, W. Page Faulk, M.D., F.R.C. Path., Patrizia Gargiulo, M.D., John A. McIntyre, Ph.D., M.R.C. Path., and Nils U. Bang, M.D.

Number 2

NEWER STRATEGIES IN THE MANAGEMENT OF THROMBOTIC DISORDERS: I

Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D.,
H. Klaus Breddin, M.D., and Jacques Caen, M.D.

- Overview of the Management of Thrombotic Disorders,** Alexander S. Gallus, M.D.
Current Perspectives in the Treatment of Thrombotic Disorders, L. Drouet, M.D. and Jaque P. Caen, M.D.
Importance of Fibrin Specificity in Therapeutic Thrombolysis and the Rationale of Using Sequential and Synergistic Combinations

- of Tissue Plasminogen Activator and Pro-Urokinase, Victor Gurewich, M.D.
- Development of Anisoylated Plasminogen-Streptokinase Activator Complex from the Acyl Enzyme Concept, Robin Fears, Ph.D.
- Polypharmacologic Interactions in the Management of Thrombosis, Gustav V.R. Born, M.D., Ph.D.
- Current Perspectives in the Antiplatelet Therapy of Thrombotic Disorders, H. Klaus Breddin, M.D.
- Update on the Pharmacology of Pentoxifylline and Its Combination with Low-Dose Acetylsalicylic Acid (HWA 5112), D. Seiffge, D.V.M. and K.U. Weithmann, Ph.D.
- Pharmacology of Ticlopidine: A Review, Ghislain Defreyn, D.Sc., André Bernat, D.Sc., Denis Delebassee, Ph.D., and Jean-Pierre Maffrand, Ph.D.
- Ticlopidine in the Treatment of Peripheral Occlusive Arterial Disease, J.C. Arcan, M.D. and E. Panak, M.D.
- Perspective on Antiplatelet Drugs, John R. O'Brien, M.D.
- Management of Blood Loss and Heparin Rebound Following Cardiopulmonary Bypass, Roque Pifarre, M.D., Henry J. Sullivan, M.D., Alvaro Montoya, M.D., Mamdouh Bakhos, M.D., John Grieco, M.D., Bryan K. Foy, M.D., and Bradford Blakeman, M.D.
- Endothelium in Health and Disease, Hyman Engelberg, M.D.
- Effect of Platelet-Activating Factor on Platelets and Vascular Endothelium, Pierre Braquet, Ph.D., D.Sc., R. Bourgain, Ph.D., and J.M. Mencia-Huerta, Ph.D.
- Endothelial Cell Interactions with Heparin, Gerard Tobelem, M.D.
- Endothelial Cell Seeding in the Management of Vascular Thrombosis, Malcolm B. Herring, M.D., Rebecca Compton, C.S.T., C.S.A., Daniel R. Legrand, M.D., and Austin L. Gardner, M.D.
- Vascular Grafting in the Management of Thrombotic Disorders, Howard P. Greisler, M.D. and Dae Un Kim, M.D.
- Perturbation of Endothelial Functions by Ionizing Irradiation: Effects on Prostaglandins, Chemoattractants, and Mitogens, Amiram Eldor, M.D., Zvi Fuks, M.D., Yaacov Matzner, M.D., Larry D. Witte, Ph.D., and Israel Vlodavsky, Ph.D.
- Inhibition of Tissue Plasminogen Activator Inhibitor by Defibrotide in Atherosclerotic Patients, Francesco Violi, M.D., Domenico Ferro, M.D., Cesare Alessandri, M.D., Claudio Quintarelli, M.D., Mirella Saliola, M.D., and Francesco Balsano, M.D.
- Antithrombotic Drugs in Pelvic Surgery, Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., and Umberto Cornelli, M.D.
- Abstracts of Articles Presented at the Symposium on "New Strategies in the Management of Thrombotic Disorders"

Number 3

NEWER STRATEGIES IN THE MANAGEMENT OF THROMBOTIC DISORDERS: II

Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., H. Klaus Breddin, M.D., and Jacques Caen, M.D.

- Thrombosis and Virchow's Triad: What is Established?, H. Klaus Breddin, M.D.
- The Quest for Thromboresistant Materials, Paul Didisheim, M.D.
- Postoperative Deep Vein Thrombosis: Current Clinical Considerations, Joseph A. Caprini, M.D. and Robert A. Natanson, M.D.
- Thrombectomy, Lysis, or Heparin Treatment: Concurrent Therapies of Deep Vein Thrombosis: Therapy and Experimental Studies, H. Stiegler, M.D., H. Arbogast, M.D., S. Nees, M.D., A. Halder, M.D., A. Grau, M.D., and H. Riess, M.D.
- A New Mechanical Device for the Prevention of Thrombotic Problems in Microsurgery, Krishna Narayanan, M.D., M.D. Liang, M.D., and D. Shichman, P.E.
- The Medicinal Leech: Historical Perspectives, Stephen L. Adams,

M.D., F.A.C.P., F.A.C.E.P.

- Thrombin Interactions with Hirudin, John W. Fenton II, Ph.D.
- Development of Hirudin as an Antithrombotic Agent, Fritz Markwardt, M.D., Ph.D.
- Comparison of Hirudins, Ernst Fink, Ph.D.
- Production and Evaluation of Recombinant Hirudin, M. Courtney, Ph.D., G. Loison, Ph.D., Y. Lemoine, Ph.D., N. Riehl-Bellon, Ph.D., E. Degryse, Ph.D., S.W. Brown, Ph.D., J.-P. Cazenave, Ph.D., G. Defreyn, Ph.D., D. Delebassee, Ph.D., A. Bernat, Ph.D., J.-P. Maffrand, Ph.D., and C. Roitsch, Ph.D.
- Biology of Recombinant Hirudin (CGP 39393): A New Prospect in the Treatment of Thrombosis, Mark Talbot, Ph.D.
- Biochemistry and Genetic Engineering of Hirudin, Paul H. Johnson, Ph.D., Ping Sze, M.S., Richard Winant, M.S., Philip W. Payne, Ph.D., and Jerome B. Lazar, Ph.D.
- Development of Recombinant Hirudin as a Therapeutic Anticoagulant and Antithrombotic Agent: Some Objective Considerations, Jeanine M. Walenga, Ph.D., Roque Pifarre, M.D., Debra A. Hoppensteadt, B.S., M.T. (ASCP), and Jawed Fareed, Ph.D.
- Impact of Biotechnology on the Diagnostics of Thrombotic Disorders, James J. Carroll, Ph.D.
- Clinical Pharmacology of the Thrombolytic Enzyme Preparation Brinase, E. Peter Frisch, M.D.
- Therapeutic Use of Antithrombin III in Shock and Disseminated Intravascular Coagulation, Helmut Vinazzer, M.D.
- Protein C and Protein S, Hau C. Kwaan, M.D.
- Abstracts of the Symposium on Newer Strategies in the Management of Thrombotic Disorders

Number 4

NEWER STRATEGIES IN THE MANAGEMENT OF THROMBOTIC DISORDERS: III

Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., H. Klaus Breddin, M.D., and Jacques Caen, M.D.

- Structure and Activity of Heparin and Its Fragments: An Overview, Jean Choay, D. Pharm.
- Therapeutic Potential of Non-Heparin Glycosaminoglycans of Natural Origin, P. Bianchini, Ph.D.
- Synopsis of the Anticoagulant and Antithrombotic Profile of the Low Molecular Weight Heparinoid Org 10172 in Experimental Models, D.G. Meuleman, Ph.D.
- Laboratory Control of Heparin and Heparin Fragment Treatment: An Experimental Study, Christian Doutremepuich, M.D., Ph.D., M.C. Lalanne, M.S., M. Guyot, Ph.D., F. Doutremepuich, M.D., O. De Sèze, M.S., and Francis Toulemonde, M.D.
- Comparative Antithrombotic and Hemorrhagic Effects of Dermatan Sulfate, Heparan Sulfate, and Heparin, Debra Hoppensteadt, B.S., M.T. (ASCP), Adrienne Racanelli, B.A., Jeanine M. Walenga, Ph.D., and Jawed Fareed, Ph.D.
- In Vitro Protamine Neutralization Profiles of Heparins Differing in Source and Molecular Weight, Adrienne Racanelli, B.A., Debra A. Hoppensteadt, B.S., M.T. (ASCP), and Jawed Fareed, Ph.D.
- Potentiality by Heparin Fragment CY 222(CHOAY) of Thrombolysis Induced by Human Tissue-Type Plasminogen Activator, I. Juhan-Vague, M.D., Ph.D., J.M. Stassen, Ph.D., M.C. Alessi, M.D., A. Elias, M.D., M.F. Aillaud, Ph.D., A. Serradimigni, M.D., and Desiree Collen, M.D., Ph.D.
- Strategy for the Development of the Low Molecular Weight Heparin Fraction CY 216 in the Prevention of Postoperative Deep Vein Thromboses in General Surgery, Francis Toulemonde, M.D.
- Low Molecular Weight Heparins and Bleeding, H. Klaus Breddin, M.D.

Clinical Potential of Low Molecular Weight Heparins, Harry L. Messmore, Jr., M.D.

Descriptive Analysis of the European Fraxiparin Study, M. Bieghold, Ph.D., for the European Fraxiparin Study Group

Comparative Human Pharmacology of Low Molecular Weight Heparins, J. Harenberg, M.D., G. Stehle, M.D., J. Augustin, M.D., and R. Zimmermann, M.D.

An Objective Evaluation of the Clinical Potential of Low Molecular Weight Heparins in the Prevention of Thromboembolism, Sylvia Haas, M.D. and Gerhard Blümel, M.D.

Fibrinolytic and Thrombolytic Parameters in Patients with Deep Vein Thrombosis Treated by Low Molecular Weight and Standard Heparin, Rene Faivre, M.D., Eric Neuhart, M.D., Massoud Mirshahi, Ph.D., Mannoucher Mirshahi, Ph.D., Claudine Soria, Ph.D., Jeanette Soria, Ph.D., Jean Pierre Bassand, M.D., Jacques P. Caen, M.D., and Jean Pierre Maurat, M.D.

Chemical and Biological Heterogeneity in Low Molecular Weight Heparins: Implications for Clinical Use and Standardization, Jawed Fareed, Ph.D., Jeanine M. Walenga, Ph.D., Debra Hoppensteadt, B.S.(ASCP), Adrienne Racanelli, B.A., and Erwin Coyne, Ph.D.

Use of Defibrotide in the Treatment of Acute Myocardial Infarction, F. Milazotto, M.D., M. Carelli, M.D., C. Citone, M.D., G. Di Marcotullio, M.D., P. Giampaolo, M.D., U. Malinconico, M.D., C. Polizzi, M.D., M. Tubaro, M.D., E. Giovannini, M.D., L. Boccardi, M.D., G. Minardi, M.D., G. Biffani, M.D., C. De Rubertis, M.D., M. Nazzari, M.D., and U. Cornelli, M.D.

Treatment of Acute Myocardial Infarction with Defibrotide, G. Mattioli, M.D., C. Capello, M.D., and M.T. Fusaro, M.D.

Scholarly Potpourri, Genesio Muvano, Ph.D. and Ernst Wenzel, M.D.

Author Index and Cumulative Table of Contents